MedTrace Logo

DCE-MRI for Assessment of Response to TACE of HCC

NCT02878109 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2021-08-06

No results posted yet for this study

Summary

This study is conducted to evaluate dynamic contrast-enhanced MRI to quantify the efficacy of trans-arterial chemoembolization by comparing imaging results before and after treatment for at least one hepatic tumor and to look at blow flow curves of the free-breathing MRI before treatment.

Conditions

  • Carcinoma, Hepatocellular

Interventions

DEVICE

Post-treatment phase group

4D-THRIVE and 4D-FLOW using magnetic resonance imaging (MRI)

DEVICE

Pre-treatment phase group

4D-THRIVE and 4D-FLOW using magnetic resonance imaging (MRI)

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Centre de Recherche du Centre Hospitalier de l'Université de Montréal

    collaborator OTHER

  • Centre hospitalier de l'Université de Montréal (CHUM)

    lead OTHER

Principal Investigators

  • An Tang, MD, MSc · Centre hospitalier de l'Université de Montréal (CHUM)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02878109 on ClinicalTrials.gov